Professor M. Akhter Hossain completed his Ph.D. in 2001 from the Tokyo Institute of Technology (Japan) and undertook postdoctoral studies at Joseph Fourier University (France) and the Howard Florey Institute (Australia). He has been the Head of the Insulin Peptides Laboratory since 2012 at the now-Florey Institute of Neuroscience and Mental Health, University of Melbourne. He has published >165 peer-reviewed articles (from 2000 to 2023) including several articles in prestigious journals such as Chemical Reviews, Journal of the American Chemical Society, Angewandte Chemie International Edition, Nature Communications, PNAS, Chemical Science, and Journal of Medicinal Chemistry. He currently holds two CIA NHMRC Ideas Grants and attracted a total of 10 ARC/NHMRC (over $8 million) in his career as Principal Investigator. He is the recipient of numerous awards including the Pathway to Impact 2023 award by the Florey. He is the current co-chair of the Solid Phase Synthesis Symposium (solidphase.org), a Victorian representative of the Australian Peptide Society, an international advisory board member of relaxin symposium 2023, and ex-president of the Peptide User Group (Melbourne). He is an Associate Editor/ Editorial Board Member of the five international journals. Eight of his discoveries have been patented to date. He is an advisor of three pharma companies including “Relaxera” Biopharma based in Germany which is developing relaxin for the treatment of heart failure. His research group is interested in designing peptidomimetics and developing novel chemical methods for preparing therapeutic insulin and insulin-like relaxin peptides.